Study of Neoantigen-specific Adoptive T Cell Therapy for Newly Diagnosed MGMT Negative Glioblastoma Multiforme (GBM)

Inclusion Criteria: * Newly diagnosed MGMT unmethylated glioblastoma multiforme (no prior treatment) * Sufficient cancer tissue obtained to allow for manufacture of autologous cancer cell vaccines * The attenuated autologous cancer cell product generated has satisfied the product release criteria as determined by the sponsor quality control department * Medical history, physical examination and laboratory testing performed within approximately 7 days before enrollment revealing kidney and liver organ function within normal limits * not currently receiving glucocorticoids and have been off glucocorticoids for at least 24 hours prior to vaccination as well as when they receive the T cell infusion. * Patient function assessment (Karnofsky score is \> 60) * a life expectancy of \> 12 weeks. * Hemoglobin is \> 10 g/dL (may be transfused) * White blood cell count is \> 3,000 cells/microliter (mcL) of blood. * Platelet count is \> 100,000 platelets per mcL of blood (transfusion independent) * Lymphocyte count is \> 1,000 cells/mcL of blood. Exclusion Criteria: * another concomitant life-threatening disease (not including glioblastoma multiforme) * a second malignancy that is not in remission as determined by the clinical investigator. Exception: squamous or basal cell carcinoma of the skin. * requirement for treatment with glucocorticoids to control brain swelling * presence of active autoimmune disease that is currently being actively treated. * psychological, familial, sociological or geographical conditions that do not permit adequate medical follow-up and compliance with the study protocol. * Current pregnancy or a plan to become pregnant within 1-year following the study.